14 Nov 2017 07:00
Silence Therapeutics' 2017 Capital Markets Day
14 November 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will today host a Capital Markets Day for analysts, investors and media from 2:15pm to 6:00pm GMT at ME London Hotel, Strand, London WC2R 1HA.
At the meeting, Silence will provide an update on its proprietary and innovative RNAi technology platform and on selected pipeline programmes (Iron Overload Disorders and Alcohol Use Disorder), as well as an overview of the Company's strategy and operational setup. Speakers from the Company will include:
· Dr Annalisa Jenkins, Board Chair
· Ali Mortazavi, Chief Executive Officer
· Dr Torsten Hoffmann, Chief Operating Officer
· Dr Dmitry Samarsky, Chief Scientific Officer
· Dr Ulrich Zügel, Head of Preclinical Drug Discovery
No material new information will be provided during the presentations.
Following the Company presentations, Silence will host a panel discussion on genomics, big data and ways to harness outcomes with genetic medicines such as RNAi. Five key opinion leaders from relevant fields will form the panel.
All presentation materials will be available on the company website at www.silence-therapeutics.com shortly after the event has concluded.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert
| Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
SLN.L (SLN)